DK4225753T3 - Potente og selektive forbindelser som modulatorer af serotonin-1B-receptorer - Google Patents

Potente og selektive forbindelser som modulatorer af serotonin-1B-receptorer Download PDF

Info

Publication number
DK4225753T3
DK4225753T3 DK21789678.6T DK21789678T DK4225753T3 DK 4225753 T3 DK4225753 T3 DK 4225753T3 DK 21789678 T DK21789678 T DK 21789678T DK 4225753 T3 DK4225753 T3 DK 4225753T3
Authority
DK
Denmark
Prior art keywords
serotonin
modulators
potent
receptors
selective compounds
Prior art date
Application number
DK21789678.6T
Other languages
Danish (da)
English (en)
Inventor
Laria Julio Castro-Palomino
Gómez Juan Alberto Camacho
Risueño Ruth Muñoz
Lise Clément-Demange
Original Assignee
Leukos Biotech S L
Fundacio Inst De Recerca Contra La Leucemia Josep Carreras
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leukos Biotech S L, Fundacio Inst De Recerca Contra La Leucemia Josep Carreras filed Critical Leukos Biotech S L
Application granted granted Critical
Publication of DK4225753T3 publication Critical patent/DK4225753T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK21789678.6T 2020-10-08 2021-10-07 Potente og selektive forbindelser som modulatorer af serotonin-1B-receptorer DK4225753T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20382888 2020-10-08
PCT/EP2021/077660 WO2022074103A1 (en) 2020-10-08 2021-10-07 Potent and selctive compounds as serotonin 1b receptor modulators

Publications (1)

Publication Number Publication Date
DK4225753T3 true DK4225753T3 (da) 2024-08-19

Family

ID=73030029

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21789678.6T DK4225753T3 (da) 2020-10-08 2021-10-07 Potente og selektive forbindelser som modulatorer af serotonin-1B-receptorer

Country Status (21)

Country Link
US (2) US12540133B2 (enExample)
EP (2) EP4225753B1 (enExample)
JP (1) JP7687636B2 (enExample)
KR (1) KR20230107566A (enExample)
CN (1) CN116635390B (enExample)
AU (1) AU2021356114A1 (enExample)
CA (1) CA3194700A1 (enExample)
CL (1) CL2023001021A1 (enExample)
DK (1) DK4225753T3 (enExample)
ES (1) ES2985416T3 (enExample)
FI (1) FI4225753T3 (enExample)
HR (1) HRP20241184T1 (enExample)
HU (1) HUE068199T2 (enExample)
IL (1) IL301806B2 (enExample)
LT (1) LT4225753T (enExample)
MX (1) MX2023004116A (enExample)
PL (1) PL4225753T3 (enExample)
PT (1) PT4225753T (enExample)
RS (1) RS65956B1 (enExample)
SI (1) SI4225753T1 (enExample)
WO (1) WO2022074103A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102993831B1 (ko) 2020-10-08 2026-07-23 머크 샤프 앤드 돔 엘엘씨 신규 디아실글리세리드 o-아실트랜스퍼라제 2 억제제로서의 옥스인돌 유도체의 제조
CN117903116A (zh) * 2021-08-27 2024-04-19 杭州阿诺生物医药科技有限公司 细胞周期蛋白k降解剂
JP2026521568A (ja) 2023-06-16 2026-06-30 レウコス バイオテク ソシエダッド リミターダ 5-htr1b調節因子を用いた固形腫瘍の治療

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW240217B (enExample) 1992-12-30 1995-02-11 Glaxo Group Ltd
US5801170A (en) 1993-12-07 1998-09-01 Smithkline Beecham Plc Heterocyclic biphenylylamides useful as 5HT1D antagonists
ZA985542B (en) 1997-07-03 1999-04-07 Smithkline Beecham Corp Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents
SK492001A3 (en) 1998-07-20 2001-08-06 Merck Patent Gmbh Biphenyl derivatives
HUP0302966A2 (hu) 2000-07-31 2003-12-29 Smithkline Beecham P.L.C. Karboxamid-vegyületek és alkalmazásuk humán 11CBY receptor antagonistákként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
WO2007057742A2 (en) 2005-11-18 2007-05-24 Pfizer Products Inc. Novel piperazinone derivatives
WO2007077457A2 (en) 2006-01-06 2007-07-12 The Royal Veterinary College Treatment of equine laminitis with 5-ht1b/ 1d antagonists
EP3348266A1 (en) 2017-01-16 2018-07-18 Leukos Biotech, S.L. Combination therapy for treating cancer

Also Published As

Publication number Publication date
US20260138974A1 (en) 2026-05-21
US20240166639A1 (en) 2024-05-23
WO2022074103A1 (en) 2022-04-14
KR20230107566A (ko) 2023-07-17
CL2023001021A1 (es) 2023-11-24
FI4225753T3 (fi) 2024-08-29
CN116635390A (zh) 2023-08-22
CN116635390B (zh) 2026-03-27
ES2985416T3 (es) 2024-11-05
CA3194700A1 (en) 2022-04-14
JP7687636B2 (ja) 2025-06-03
LT4225753T (lt) 2024-08-26
IL301806B1 (en) 2026-01-01
US12540133B2 (en) 2026-02-03
EP4445901A3 (en) 2024-12-04
PT4225753T (pt) 2024-08-30
HRP20241184T1 (hr) 2024-11-22
EP4445901A2 (en) 2024-10-16
SI4225753T1 (sl) 2024-10-30
EP4225753A1 (en) 2023-08-16
IL301806A (en) 2023-05-01
AU2021356114A9 (en) 2024-09-12
IL301806B2 (en) 2026-05-01
PL4225753T3 (pl) 2024-11-18
EP4225753B1 (en) 2024-07-31
JP2023547346A (ja) 2023-11-10
HUE068199T2 (hu) 2024-12-28
AU2021356114A1 (en) 2023-05-18
RS65956B1 (sr) 2024-10-31
MX2023004116A (es) 2023-06-13

Similar Documents

Publication Publication Date Title
IL311454A (en) Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
DK4069691T3 (da) Substituerede tetrahydrofuraner som modulatorer af natriumkanaler
DK4061812T3 (da) Forbindelser som er nyttige som inhibitorer af heliosprotein
DK3433234T3 (da) Allosteriske modulatorer af nicotinacetylcholinreceptorer
DK3532486T3 (da) Antistof-forbundne cykliske peptidtyrosin-tyrosinforbindelser som modulatorer af neuropeptid-y- receptorer
IL286620A (en) T cell receptors and methods of use thereof
DK3847844T3 (da) Transport af datastrømme over cellulære netværk
DK3698924T3 (da) Fremgangsmåde til dokumenteret spænding eller efterspænding af en skrueforbindelse
DK3788043T3 (da) Spiropiperidin som allosteriske modulatorer af nicotinacetylcholinreceptorer
DK3740475T3 (da) Fremgangsmåde til fremstilling af somatostatinmodulatorer
IL286032A (en) T cell receptors and methods of use thereof
IL286041A (en) T cell receptors and methods of use thereof
EP4103564A4 (en) P2X3 MODULATORS
IL286046A (en) T cell receptors and methods of use thereof
IL286044A (en) T cell receptors and methods of use thereof
EP4196639A4 (en) VIBRATORY SCREED
DK4161927T3 (da) Spiroforbindelser som melanocortin-4-receptorantagonister og anvendelser deraf
PL4117784T3 (pl) Związki stanowiące modulator gpr52
IL286039A (en) T cell receptors and methods of use thereof
EP4176639C0 (en) END-TO-END TIME SYNCHRONIZATION FOR CLOUD SERVICES
IL286042A (en) T cell receptors and methods of use thereof
DK4208048T3 (da) Fremgangsmåde til blegning af tobak
DK3994970T3 (da) Enhed til adskillelse af udlægningsmateriale
EP4146173A4 (en) FORMULATIONS OF PYRIMIDINE-CYCLOHEXYL-GLUCOCORTICOID RECEPTOR MODULATORS
DK3900823T3 (da) Fremgangsmåde til regenerering af carbonholdig adsorptionsmiddel